BioMarin Raises 2026 Revenue Guidance After Q1 Beat at $766 Million
BioMarin boosts full-year revenue outlook to $3.825-$3.925 billion following strong Q1 results and acquisition-driven growth. BioMarin Pharmaceutical reported Q1 2026 revenues of $766 million, driven by the acquisition of Amicus Therapeutics and expanded portfolio products